RAYNHAM, Mass., Dec. 7, 2017 /PRNewswire/ — OMNIlife science, Inc. (“OMNI”), a privately-held, established medical technology company targeting the $15 billion global hip and knee replacement device market, reported today that, after more than 100 cases, the positive clinical value of the OMNIBotics® Active Spacer is coming into sharper focus. The multi-center U.S. study is evaluating this breakthrough technology that combines the accuracy of robotic-assisted bone cutting with active soft tissue management. The study currently involves five sites with additional sites to be added over the next several months.
The results from the initial four U.S. sites reflect the positive outcomes experienced in the Australian pilot program underway since March. “The excellent experience that has been seen in the US parallels the experience we have seen over the first 6 months,” said Dr. Brett Fritsch, MD, FRACS, in Sydney. “Our patients all seem to be doing very well. They are achieving a good range of motion and excellent mobility at the early stage of their recovery.”
“Our theory is that less ligament surgery will create less pain and swelling after surgery, faster recovery and better motion,” said Dr. Jeffrey Lawrence, MD of Viroqua, WI. “We can now balance the knee in real time, while also decreasing the amount of surgery required.”
The OMNIBotics® Active Spacer is currently the only system enabling the surgeon to predictively balance the ligaments through dynamic real-time feedback across the entire range of motion and deliver the accuracy of computer calculated, robotic-assisted bone cutting. Engineered to optimize OMNI’s Apex™ Knee replacement implants, the system provides a customized procedure designed to maximize patient outcomes.
“With many studies indicating that a significant percentage of knee replacement patients are not fully satisfied with the results, the OMNIBotics Active Spacer technology provides the surgeon with a quantitative tool to plan bone cuts to address the resulting ligament balance,” said Christian Joly, Vice President of Robotics at OMNI. “We believe that this advanced robotic device is helping increase surgeon confidence, improve consistency, and reduce the number of soft tissue releases by creating a customized patient-specific procedure.”
OMNI is a privately held company with a proprietary robotic platform, OMNIBotics®, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is